← Signal Board

Vanda Pharmaceuticals financial statements

반다 파머슈티컬스NASDAQ:VNDA · Nasdaq · Healthcare · sector #20
$4.53-0.66%
2026-10-08 close

Vanda Pharmaceuticals's published financial data is dated 2026-10-04. 2024 revenue was $199M. 2024 operating profit was −$41M.

Reported results

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 6.91
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
6.91
Beneish M-Score
-2.25

No statistical flag

Sloan accrual
-0.48%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

4/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score4/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityWarning

OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Revenue qualityWarning

매출채권 증가율이 매출 증가율의 1.5배 초과 (3기 연속) — 매출 인식 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Cash conversion cycleWarning

현금전환주기(CCC) 5기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-7.2% → -20.5%, -13.2%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-20.5%
Interest coverage
-1.9x
Return on equity (ROE)
-3.5%

Operating margin −5pp

Operating loss
Interest coverageBase -1.9x adverse case -2.3x
Return on equity (ROE)Base -3.5% adverse case -13.4%

Revenue −15%

Interest coverage risk
Interest coverageBase -1.9x adverse case -1.6x
Return on equity (ROE)Base -3.5% adverse case -10.5%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -1.9x adverse case -1.7x
Return on equity (ROE)Base -3.5% adverse case -12%

Interest coverage limit

Already below the limit by 31.4pp

Interest coverage limit at an operating margin of 10.9%

Interest expense coverage threshold

Vanda Pharmaceuticals notifications

Quantus Signal · live data · not investment advice · Privacy Policy